
|Articles|May 14, 2014
How BMS is Doing RBM (Risk-Based Monitoring)
Author(s)Guest Blogger
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Advertisement
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
2
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
3
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




